巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Codexis

    CDXS
    6.090
    0.050
    0.90%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Codexis - 延遲價格・最後更新於 26/09 12:00
    最高位
    6.260
    最低位
    6.060
    開市價
    --
    前收市價
    6.145
    成交量(千)
    62.26
    成交額(百萬)
    3.27
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    398.86
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    42.010 - 6.040
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Codexis
    證券代碼
    CDXS.US
    所屬板塊
    Biotechnology
    公司業務
    Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products. The firm's products and services include Screening and Evolution services, Enzymes, Screening Kits. It also develops protein engineering and biocatalyst platforms such as Codeevolver, Ketoreductases, Transminases, Imine reductases, etc. The company operates in two business segments namely Performance Enzymes and Novel Biotherapeutics. It generates maximum revenue from the Performance Enzymes segment. Geographically, it derives a majority of revenue from the APAC.
    發行量
    65160679
    公司總部
    200 Penobscot Drive
    公司網址
    https://www.codexis.com
    公司電話
    +1 650 421-8100

    ARK追蹤 | 大膽押注!買入比亞迪ADR、巴菲特青睞的銀行股

    美股情報局·
    ARK追蹤 | 大膽押注!買入比亞迪ADR、巴菲特青睞的銀行股

    ARK追蹤 | 跌慌了?木頭姐發聲安撫!抄底ADPT13萬股

    美股情報局·
    ARK追蹤 | 跌慌了?木頭姐發聲安撫!抄底ADPT13萬股

    ARK追蹤 | 美股暴漲之際,木頭姐甩賣25萬股Cellectis

    美股情報局·
    ARK追蹤 | 美股暴漲之際,木頭姐甩賣25萬股Cellectis

    ARK追蹤 | 一周暴跌超36%!木頭姐繼續抄底圖森未來

    美股情報局·
    ARK追蹤 | 一周暴跌超36%!木頭姐繼續抄底圖森未來

    ARK追蹤 | 抄底ARKK?華爾街價值經理警告現在不是時機

    美股情報局·
    ARK追蹤 | 抄底ARKK?華爾街價值經理警告現在不是時機

    關於

    Codexis(CDXS.US)所屬的行業板塊為Biotechnology。
    Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products. The firm's products and services include Screening and Evolution services, Enzymes, Screening Kits. It also develops protein engineering and biocatalyst platforms such as Codeevolver, Ketoreductases, Transminases, Imine reductases, etc. The company operates in two business segments namely Performance Enzymes and Novel Biotherapeutics. It generates maximum revenue from the Performance Enzymes segment. Geographically, it derives a majority of revenue from the APAC.
    詳細公司背景可參考: https://www.codexis.com